Laboratory Aspects of Donor Screening for Fecal Microbiota Transplantation at a Korean Fecal Microbiota Bank
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Fecal microbiota transplantation (FMT) is a widely accepted alternative therapy for Clostridioides difficile infection and other gastrointestinal disorders. Thorough donor screening is required as a safety control measure to minimize transmission of infectious agents in FMT. We report the donor screening process and outcomes at a fecal microbiota bank in Korea. From August 2017 to June 2020, the qualification of 62 individuals as FMT donors was evaluated using clinical assessment and laboratory tests. Forty-six (74%) candidates were excluded after clinical assessment; high body mass index (>25) was the most common reason for exclusion, followed by atopy, asthma, and allergy history. Four of the remaining 16 (25%) candidates failed to meet laboratory test criteria, resulting in a 19% qualification rate. FMT donor re-qualification was conducted monthly as an additional safety control measure, and only three (5%) candidates were eligible for repeated donation. As high prevalence of multidrug-resistant organisms (55%) and Helicobacter pylori (44%) were detected in qualified donors during the screening, a urea breath test was added to the existing protocol. The present results emphasize the importance of implementing a donor re-qualification system to minimize risk factors not identified during initial donor screening.
Abstract
Fecal microbiota transplantation (FMT) is a widely accepted alternative therapy for Clostridioides difficile infection and other gastrointestinal disorders. Thorough donor screening is required as a safety control measure to minimize transmission of infectious agents in FMT. We report the donor screening process and outcomes at a fecal microbiota bank in Korea. From August 2017 to June 2020, the qualification of 62 individuals as FMT donors was evaluated using clinical assessment and laboratory tests. Forty-six (74%) candidates were excluded after clinical assessment; high body mass index (>25) was the most common reason for exclusion, followed by atopy, asthma, and allergy history. Four of the remaining 16 (25%) candidates failed to meet laboratory test criteria, resulting in a 19% qualification rate. FMT donor re-qualification was conducted monthly as an additional safety control measure, and only three (5%) candidates were eligible for repeated donation. As high prevalence of multidrug-resistant organisms (55%) and Helicobacter pylori (44%) were detected in qualified donors during the screening, a urea breath test was added to the existing protocol. The present results emphasize the importance of implementing a donor re-qualification system to minimize risk factors not identified during initial donor screening.
참고문헌 (20)
- Dinh A, "Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study", J Hosp Infect, 99, pp.481~486 (2018)
- Kao D, "Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial", JAMA, 318, pp.1985~1993 (2017)
- Sokol H, "Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study", Microbiome, 8, pp.12~ (2020)
- Cammarota G, "European consensus conference on faecal microbiota transplant in clinical practice", Gut, 66, pp.569~580 (2017)
- Costello SP, "Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection", Clin Infect Dis, 62, pp.908~914 (2016)
- Craven LJ, "Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome-associated diseases", Open Forum Infect Dis, 4, pp.ofx243~ (2017)
- Kassam Z, "Donor screening for fecal microbiota transplantation", N Engl J Med, 381, pp.2070~2072 (2019)
- Rode AA, "Establishing a donor stool bank for faecal microbiota transplantation: methods and feasibility", Eur J Clin Microbiol Infect Dis, 38, pp.1837~1847 (2019)
- Terveer EM, "How to: establish and run a stool bank", Clin Microbiol Infect, 23, pp.924~930 (2017)
- Woodworth MH, "Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review", Gut Microbes, 8, pp.225~237 (2017)
- "Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms"[URL]
- Cammarota G, "International consensus conference on stool banking for faecal microbiota transplantation in clinical practice", Gut, 68, pp.2111~2121 (2019)
- 권태근, "A Case of Toxic Megacolon Caused by Clostridium difficile Infection and Treated with Fecal Microbiota Transplantation", Gut and Liver, 9(2), pp.247~250 (2015), 거트앤리버 소화기연관학회협의회
- Yoon YK, "Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection", Ann Med, 51, pp.379~389 (2019)
- Chung KS, "Division of human blood safety surveillance", pp.3~5 (2016), Korea Centers for Disease Control & Prevention
- DeFilipp Z, "Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant", N Engl J Med, 381, pp.2043~2050 (2019)
- van Beurden YH, "Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection", United European Gastroenterol J, 5, pp.868~879 (2017)
- Šeligová B, "Diagnostic reliability of nested PCR depends on the primer design and threshold abundance of Helicobacter pylori in biopsy, stool, and saliva samples", Helicobacter, 25, pp.e12680~ (2020)
- Hooi JKY, "Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis", Gastroenterology, 153, pp.420~429 (2017)
- 성흥섭, "소아에서 Helicobacter pylori 대변 항원 양성 결과와 빈혈의 연관성에 대한 다기관 연구", Annals of Clinical Microbiology, 21(3), pp.58~63 (2018), 대한임상미생물학회